健帆生物(300529) - 2021 Q3 - 季度财报

Financial Performance - Revenue for Q3 2021 reached ¥593,550,456.87, a 33.19% increase compared to ¥445,657,614.95 in the same period last year[2] - Net profit attributable to shareholders was ¥242,944,880.34, reflecting a 30.07% growth from ¥186,780,990.40 year-on-year[2] - The net profit excluding non-recurring items was ¥230,969,324.74, up 26.61% from ¥182,430,082.30 in the previous year[2] - Basic earnings per share increased to ¥0.30, a rise of 30.43% compared to ¥0.23 in the same quarter last year[3] - The company reported a net cash flow from operating activities of ¥666,139,337.01, a 34.69% increase compared to ¥494,569,492.46 in the same period last year[2] - Net profit for the period was ¥862,064,846.32, a 37.77% increase year-over-year, attributed to rising sales revenue[8] - The total profit amounted to ¥1,008,578,370.98, reflecting a 36.63% increase, primarily due to increased sales revenue[8] - The net profit attributable to the parent company for Q3 2021 was ¥863,085,578.68, an increase of 37.5% compared to ¥627,410,475.05 in Q3 2020[22] - The basic earnings per share for Q3 2021 was ¥1.08, up from ¥0.79 in Q3 2020, representing a growth of 36.8%[22] - The company reported a comprehensive income total of ¥862,064,846.32 for Q3 2021, up from ¥625,716,200.23 in Q3 2020, reflecting a growth of 37.8%[22] Assets and Liabilities - Total assets as of September 30, 2021, amounted to ¥4,456,966,032.36, representing a 37.87% increase from ¥3,232,636,571.54 at the end of the previous year[3] - The company's total liabilities increased by 216.54% to ¥1,263,072,865.32, primarily due to the issuance of convertible bonds[6] - Owner's equity reached ¥3,193,893,167.04 in Q3 2021, up from ¥2,833,610,052.04 in Q3 2020, representing an increase of 12.7%[19] - Total current assets amounted to CNY 1,986,610,992.82, while total non-current assets reached CNY 1,230,059,269.12, leading to a total asset value of CNY 3,216,670,261.94[25] - Total current liabilities were CNY 330,816,522.71, and total liabilities amounted to CNY 383,060,209.90, resulting in total equity of CNY 2,833,610,052.04[26] Cash Flow - Cash flow from operating activities increased by 34.69% to ¥666,139,337.01, driven by higher sales income[9] - Cash inflow from operating activities for the current period was ¥1,946,579,527.79, an increase of 30.0% from ¥1,498,682,092.41 in the previous period[23] - Total cash inflow from investment activities was ¥2,330,043,064.21, significantly higher than ¥898,177,834.33 in the previous year[24] - The net cash flow from investment activities was -¥1,329,117,858.58, compared to -¥626,115,343.34 in the previous year, indicating increased investment outflows[24] - Cash inflow from financing activities totaled ¥1,192,629,344.86, compared to ¥119,293,871.24 in the previous year, showing a substantial increase[24] - The ending balance of cash and cash equivalents was ¥1,278,225,616.54, compared to ¥868,381,243.66 at the end of the previous year, indicating a strong liquidity position[24] Research and Development - Research and development expenses surged by 98.86% to ¥96,107,213.37, reflecting the company's expansion of its R&D team and increased investment in innovation[7] - Research and development expenses in Q3 2021 amounted to ¥96,107,213.37, which is a significant increase of 98.7% from ¥48,328,844.23 in Q3 2020[21] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 65,345, with the largest shareholder holding 43.55% of the shares[11] - The total number of restricted shares held by major shareholders at the end of the period was 291,227,519 shares, with no shares released during the period[14] - The top ten shareholders include significant holdings by individuals such as Dong Fan with 87,707,193 shares and Hong Kong Central Clearing Limited with 21,096,047 shares[12] Inventory and Accounts Receivable - The company’s inventory increased by 55.56% to ¥187,719,794.48, attributed to stockpiling for annual sales growth[6] - Accounts receivable increased significantly to CNY 317,935,742.18 from CNY 167,407,463.38, marking an increase of approximately 89.9%[16] - Inventory levels rose to CNY 187,719,794.48, up from CNY 120,672,095.51, indicating an increase of about 55.6%[16] Other Information - The company executed a total of 318,630 stock options under its incentive plan during the reporting period[15] - The company has not reported any new product launches or technological advancements during this quarter[14] - There were no new mergers or acquisitions disclosed in the latest earnings call[14] - The company has not provided specific future guidance or market expansion strategies in the current report[14] - The adjustment for the new leasing standard resulted in an increase of CNY 15,966,309.60 in both non-current assets and non-current liabilities[28] - The company has not undergone an audit for the third quarter report[29]